Loading clinical trials...
Loading clinical trials...
A Phase II Trial of Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma: BENCART Trial
Conditions
Interventions
BCD chemotherapy (Bendamustine, Carboplatin, Dexamethasone)
Start Date
May 1, 2015
Primary Completion Date
September 1, 2017
Completion Date
September 1, 2017
Last Updated
September 6, 2018
NCT07388563
NCT06561048
NCT05679895
NCT04752826
NCT06909877
NCT07356245
Lead Sponsor
Samsung Medical Center
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions